跳至主要内容
临床试验/NL-OMON56107
NL-OMON56107招募中2 期

Autoimmune epilepsy Modulated by IVIg - effects on Cortical Excitability, the AMICE study - AMICE study

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 55 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
55

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Age of 18 years and older. - Epilepsy, with at least one seizure per week at
  • baseline. - Antibodies proven in serum and/or CSF in cell-based assay and/or
  • ELISA and on immunohistochemistry. In case of anti-GAD antibodies, antibody
  • titer with ELISA has to be >10,000 IU in serum or >100 IU in CSF.

排除标准

  • - Another identified cause of epilepsy (i.e. viral/bacterial encephalitis,
  • stroke, tumor). - Severe encephalitis in which escalation of therapy
  • (second-line immunotherapy, i.e. Rituximab or Cyclophosphamide) is expected
  • within the study period (mainly anti-NMDAR encephalitis with mRS 5, at the
  • ICU). - Use of immunotherapy < 3 months ago. - Use of monoclonal antibodies < 1
  • year ago. - Premorbid mRS >=3. - Known hypersensitivity to Privigen or
  • contraindication for Privigen, i.e. IgA deficiency. - Patient and/or legal
  • representative is withholding informed consent. - Patient objects after initial
  • informed consent.

研究者

相似试验